Compare AISPW & YDESW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | AISPW | YDESW |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | 65 | 15 |
| Industry | Blank Checks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
| Metric | AISPW | YDESW |
|---|---|---|
| Price | $0.51 | $0.24 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 15.7K | 9.3K |
| Earning Date | 04-02-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,724,085.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.39 | $0.20 |
| 52 Week High | $3.24 | $2.85 |
| Indicator | AISPW | YDESW |
|---|---|---|
| Relative Strength Index (RSI) | 36.20 | 40.30 |
| Support Level | $0.42 | N/A |
| Resistance Level | $0.82 | $0.35 |
| Average True Range (ATR) | 0.10 | 0.04 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 25.00 | 27.07 |
Airship AI Holdings Inc is a robust AI-driven data management platform that solves complex data challenges for large institutions operating in dynamic and mission-critical environments with rapidly increasing volumes of data being ingested from a similarly rapidly growing number of data sources. Its primary offerings include Outpost AI, Acropolis, and Airship Command. Its offerings allow customers to manage their data across the full data lifecycle, when and where need it, using a secure permission-based architecture. Airship AI's software allows customers to view structured data both in real-time as well as to conduct searches on the structured data at a later point in time.
YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.